HK1203940A1 - Pyrrolopyridinone derivatives as ttx-s blockers ttx-s - Google Patents
Pyrrolopyridinone derivatives as ttx-s blockers ttx-sInfo
- Publication number
- HK1203940A1 HK1203940A1 HK15104385.8A HK15104385A HK1203940A1 HK 1203940 A1 HK1203940 A1 HK 1203940A1 HK 15104385 A HK15104385 A HK 15104385A HK 1203940 A1 HK1203940 A1 HK 1203940A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ttx
- blockers
- pyrrolopyridinone derivatives
- pyrrolopyridinone
- derivatives
- Prior art date
Links
- ORKUYZDMEWAUEZ-UHFFFAOYSA-N pyrrolo[3,2-b]pyridin-2-one Chemical class N1=CC=CC2=NC(=O)C=C21 ORKUYZDMEWAUEZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638085P | 2012-04-25 | 2012-04-25 | |
| JP2012260231 | 2012-11-28 | ||
| PCT/JP2013/002825 WO2013161312A1 (en) | 2012-04-25 | 2013-04-25 | Pyrrolopyridinone derivatives as ttx-s blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1203940A1 true HK1203940A1 (en) | 2015-11-06 |
Family
ID=49482654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15104385.8A HK1203940A1 (en) | 2012-04-25 | 2015-05-08 | Pyrrolopyridinone derivatives as ttx-s blockers ttx-s |
| HK15108099.6A HK1207381A1 (en) | 2012-04-25 | 2015-08-20 | Pyrrolopyridinone derivatives as ttx-s blockers ttx-s |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15108099.6A HK1207381A1 (en) | 2012-04-25 | 2015-08-20 | Pyrrolopyridinone derivatives as ttx-s blockers ttx-s |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9187475B2 (xx) |
| EP (1) | EP2841435B1 (xx) |
| JP (1) | JP6175672B2 (xx) |
| KR (1) | KR102090944B1 (xx) |
| CN (1) | CN104520296B (xx) |
| BR (1) | BR112014026283B1 (xx) |
| CA (1) | CA2871229C (xx) |
| ES (1) | ES2645984T3 (xx) |
| HK (2) | HK1203940A1 (xx) |
| IN (1) | IN2014MN02056A (xx) |
| MX (1) | MX360323B (xx) |
| RU (1) | RU2646754C2 (xx) |
| TW (1) | TWI577677B (xx) |
| WO (1) | WO2013161312A1 (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6173364B2 (ja) * | 2014-01-29 | 2017-08-02 | 大正製薬株式会社 | 部分的に飽和された含窒素複素環化合物を有効成分として含有する医薬 |
| BR112017004136B1 (pt) * | 2014-08-29 | 2022-05-03 | Chdi Foundation, Inc | Agente de imagemamento, seu uso e compostos |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| EP4331585A3 (en) * | 2015-11-02 | 2024-05-15 | Blueprint Medicines Corporation | Inhibitors of ret |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| MX2019008696A (es) * | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| SG11201908569QA (en) * | 2017-03-21 | 2019-10-30 | Arbutus Biopharma Corp | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| ES2919280T3 (es) | 2017-05-04 | 2022-07-22 | Bayer Cropscience Ag | Derivados de 2-{[2-(feniloximetil)piridin-5-il]oxi}-etanamina y compuestos relacionados como pesticidas, por ejemplo para la protección de plantas |
| LT3773589T (lt) | 2018-04-03 | 2024-02-12 | Blueprint Medicines Corporation | Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui |
| TW202038950A (zh) * | 2018-12-26 | 2020-11-01 | 日商拉夸里亞創藥股份有限公司 | 作為Nav1.7及Nav1.8阻斷劑之雜環衍生物 |
| JP7413346B2 (ja) | 2019-03-06 | 2024-01-15 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002081446A1 (en) * | 2001-04-06 | 2002-10-17 | Daewoong Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof |
| AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| CA2633329A1 (en) * | 2006-01-23 | 2007-07-26 | Pfizer Limited | Pyridine derivatives as sodium channel modulators |
| DE102006025318A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung |
| US20110237567A9 (en) | 2006-10-12 | 2011-09-29 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| RU2537549C2 (ru) * | 2008-01-04 | 2015-01-10 | Интелликайн ЭлЭлСи | Некоторые химические структуры, композиции и способы |
| AU2010341573B2 (en) * | 2009-12-22 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| WO2011083316A1 (en) * | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
| WO2012020567A1 (en) * | 2010-08-09 | 2012-02-16 | Raqualia Pharma Inc. | Acyl piperazine derivatives as ttx-s blockers |
| EP2630122B1 (en) * | 2010-10-18 | 2016-11-30 | RaQualia Pharma Inc | Arylamide derivatives as ttx-s blockers |
| US20130203756A1 (en) * | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
-
2013
- 2013-04-25 JP JP2014551356A patent/JP6175672B2/ja active Active
- 2013-04-25 MX MX2014012915A patent/MX360323B/es active IP Right Grant
- 2013-04-25 KR KR1020147032850A patent/KR102090944B1/ko active IP Right Grant
- 2013-04-25 BR BR112014026283-7A patent/BR112014026283B1/pt active IP Right Grant
- 2013-04-25 IN IN2056MUN2014 patent/IN2014MN02056A/en unknown
- 2013-04-25 US US14/394,532 patent/US9187475B2/en active Active
- 2013-04-25 ES ES13782571.7T patent/ES2645984T3/es active Active
- 2013-04-25 CN CN201380022248.1A patent/CN104520296B/zh active Active
- 2013-04-25 CA CA2871229A patent/CA2871229C/en active Active
- 2013-04-25 TW TW102114779A patent/TWI577677B/zh active
- 2013-04-25 EP EP13782571.7A patent/EP2841435B1/en active Active
- 2013-04-25 WO PCT/JP2013/002825 patent/WO2013161312A1/en active Application Filing
- 2013-04-25 RU RU2014147243A patent/RU2646754C2/ru active
-
2015
- 2015-05-08 HK HK15104385.8A patent/HK1203940A1/xx unknown
- 2015-08-20 HK HK15108099.6A patent/HK1207381A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX360323B (es) | 2018-10-29 |
| BR112014026283B1 (pt) | 2022-08-02 |
| IN2014MN02056A (xx) | 2015-08-21 |
| US20150094306A1 (en) | 2015-04-02 |
| TW201350480A (zh) | 2013-12-16 |
| JP2015514679A (ja) | 2015-05-21 |
| EP2841435B1 (en) | 2017-09-06 |
| BR112014026283A2 (pt) | 2017-06-27 |
| RU2646754C2 (ru) | 2018-03-07 |
| WO2013161312A1 (en) | 2013-10-31 |
| MX2014012915A (es) | 2014-11-25 |
| EP2841435A4 (en) | 2015-11-11 |
| CN104520296A (zh) | 2015-04-15 |
| KR102090944B1 (ko) | 2020-03-19 |
| RU2014147243A (ru) | 2016-06-10 |
| CA2871229C (en) | 2020-10-27 |
| JP6175672B2 (ja) | 2017-08-09 |
| CN104520296B (zh) | 2016-11-16 |
| US9187475B2 (en) | 2015-11-17 |
| CA2871229A1 (en) | 2013-10-31 |
| TWI577677B (zh) | 2017-04-11 |
| ES2645984T3 (es) | 2017-12-11 |
| EP2841435A1 (en) | 2015-03-04 |
| HK1207381A1 (en) | 2016-01-29 |
| KR20150006001A (ko) | 2015-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200040I1 (hu) | Benzimidazol-prolin származékok | |
| HK1205740A1 (en) | Pyrrolotriazinone derivatives | |
| HK1207381A1 (en) | Pyrrolopyridinone derivatives as ttx-s blockers ttx-s | |
| HK1207380A1 (en) | Amide derivatives as ttx-s blockers ttx-s | |
| ZA201502175B (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| HK1212697A1 (zh) | 作為 阻斷劑的吡唑並吡啶衍生物 | |
| HK1202544A1 (zh) | 芳基乙炔基衍生物 | |
| SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
| HK1207376A1 (en) | Arylethynyl derivatives |